4(5)-Methyl-5(4)-phenyl-imidazol | 826-83-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4(5)-Methyl-5(4)-phenyl-imidazol
• 英文别名: 5-methyl-4-phenylimidazole；5-methyl-4-phenyl-1H-imidazole
• CAS: 826-83-5
• 化学式: C₁₀H₁₀N₂
• mdl: MFCD01924684
• 分子量: 158.203
• InChiKey: KYKQVLBOPNFHSV-UHFFFAOYSA-N

物化性质

• 熔点：
  185 °C
• 沸点：
  361.8±11.0 °C(Predicted)
• 密度：
  1.109±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4(5)-Methyl-5(4)-phenyl-imidazol 在 硫酸 、 铂 作用下， 生成 4-cyclohexyl-5-methyl-1(3)H-imidazole
  参考文献：
  名称：

  Schubert; Hofmann, Journal fur praktische Chemie (Leipzig 1954), 1959, vol. <4> 7, p. 119,130

  摘要：

  DOI：
• 作为产物：
  描述：

  6-Chloro-2-methyl-3-phenylpyrazine 在 氢氧化钾 、 sodium azide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 19.0h， 生成 4(5)-Methyl-5(4)-phenyl-imidazol
  参考文献：
  名称：

  Watanabe, T.; Nishiyama, J.; Hirate, R., Journal of Heterocyclic Chemistry, 1983, vol. 20, p. 1277 - 1281

  摘要：

  DOI：

文献信息

• Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
  申请人：Neurogen Corporation, Corporation of the State of Delaware

  公开号：US20030018025A1

  公开（公告）日：2003-01-23

  Disclosed are compounds of the formula: 1 wherein R 1 represents optionally substituted aryl, heteroaryl, arylalkyl, or cycloalkyl groups; X, Z, and Y are optionally substituted nitrogen or carbon atoms; R 3 and R 4 are organic or inorganic substitutents which may togther form ring structutes; m is zero, one or two; and R 5 and R 6 are are organic or inorganic substituents; and the pharmaceutically acceptable addition salts thereof, which compounds are highly selective partial agonists or antagonists at brain dopamine receptor subtypes or prodrugs thereof and are useful in the diagnosis and treatment of affective disorders such as schizophrenia and depression as well as certain movement disorders such as Parkinsonism.

  揭示了以下式的化合物： 其中R1代表可选择地取代的芳基、杂环芳基、芳基烷基或环烷基基团；X、Z和Y为可选择地取代的氮或碳原子；R3和R4为有机或无机取代基，可能共同形成环结构；m为零、一或二；R5和R6为有机或无机取代基； 以及其药学上可接受的盐， 这些化合物是高度选择性的部分激动剂或拮抗剂，作用于脑多巴胺受体亚型或其前药，并可用于诊断和治疗情感障碍，如精神分裂症和抑郁症，以及某些运动障碍，如帕金森病。
• Heterocyclic compounds as inhibitors of factor VIIa
  申请人：Glunz W. Peter

  公开号：US20060211720A1

  公开（公告）日：2006-09-21

  The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及抑制丝氨酸蛋白酶的化合物。具体而言，它涉及新颖的杂环化合物，或其立体异构体或药用可接受的盐、溶剂合物或前药形式，这些化合物可用作凝血级联中丝氨酸蛋白酶的选择性抑制剂；例如凝血酶、第VIIa因子、第Xa因子、第XIa因子、第IXa因子和/或血浆激肽。具体而言，它涉及第VIIa因子抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们的方法。
• 6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepines derivatives as histamine H4 receptor ligands
  申请人：BIOPROJECT

  公开号：US09255101B2

  公开（公告）日：2016-02-09

  The present patent application concerns new ligands of the H4-receptor, their process of preparation and their therapeutic use.

  本专利申请涉及新的H4受体配体，其制备过程及其治疗用途。
• Novel synthesis of divergent aryl imidazoles from ketones involving copper-catalyzed α-amination and oxidative C–C bond cleavage
  作者：Jiangkun Huang、Lan Luo、Naiguo Xing、Linghui Gu、Chen Li、Qiao Han、Shilong Zheng、Ling He

  DOI：10.1039/d0ra01408g

  日期：——

  A one-pot synthesis, initiated by a copper salt with inorganic (NH4)2CO3 as the nitrogen source, forms divergent aryl imidazole derivatives from ketones via α-amination and oxidative C–C bond cleavage reactions. The approach provides a simple and rapid synthesis of imidazole derivatives and has certain versatility.

  以铜盐和无机(NH 4 ) 2 CO 3作为氮源引发的一锅合成，通过α-胺化和氧化C-C键断裂反应从酮形成不同的芳基咪唑衍生物。该方法提供了一种简单、快速的咪唑衍生物合成方法，具有一定的通用性。
• Indolinones having kinase-inhibiting activity
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06043254A1

  公开（公告）日：2000-03-28

  The present invention relates to indolinones of general formula ##STR1## wherein R.sub.1 to R.sub.3 are defined in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof which have valuable pharmacological properties, particularly an inhibiting effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

  本发明涉及一般式##STR1##中R.sub.1至R.sub.3的定义如权利要求1所述，其异构体和盐，特别是具有有价值的药理特性的生理上可接受的盐，特别是对各种激酶和cycline/CDK复合物以及各种肿瘤细胞增殖具有抑制作用的盐，含有这些化合物的药物组合物，它们的用途和制备它们的方法。